Want to see NUS full AI Analyst Report?
Top Page
Nu Skin
(NYSE:NUS)
Select Model
Select Model
Rating:51Neutral
Price Target:
$5.00
▼(-1.57% Downside)
Action:Reiterated
Date:08/11/26
Overall score reflects pressured financial performance (revenue declines, TTM net loss, and sharply lower free cash flow) as the biggest headwind. Earnings-call signals are modestly supportive due to Prysm iO traction, cost actions, and maintained adjusted EPS guidance, but margin pressure, recruiting weakness, FX headwinds, and delayed India expansion temper confidence. Technicals remain weak-to-neutral, while valuation is helped by the dividend but limited by loss-driven negative P/E.
Positive Factors
Gross Margin Strength
Sustainably high core gross margins (~77.7%) indicate strong unit economics and pricing power in skincare and consumables. This margin buffer supports profitability recovery even if revenue growth is slow, preserves cash flow potential, and provides room to invest in product and field initiatives.
Negative Factors
Revenue Decline and Profitability Pressure
A multi-year top-line decline and a substantial TTM net loss undermine operating leverage and return on capital. Persistent revenue erosion reduces scale benefits, makes fixed-cost absorption harder, and constrains the firm's ability to sustainably fund distributor incentives and growth investments.
Read all positive and negative factors
Positive Factors
Negative Factors
Gross Margin Strength
Sustainably high core gross margins (~77.7%) indicate strong unit economics and pricing power in skincare and consumables. This margin buffer supports profitability recovery even if revenue growth is slow, preserves cash flow potential, and provides room to invest in product and field initiatives.
Read all positive factors
Nu Skin Key Performance Indicators (KPIs)
Any
Revenue by Segment
Breaks down sales across the company’s segments so you can see where growth is coming from and how diversified the business is. For Nu Skin, this reveals dependence on specific regions, product categories, or distributor channels, helps identify fast‑growing versus stagnant areas, and flags concentration or seasonal risks that could affect future top‑line momentum.
Breaks down sales across the company’s segments so you can see where growth is coming from and how diversified the business is. For Nu Skin, this reveals dependence on specific regions, product categories, or distributor channels, helps identify fast‑growing versus stagnant areas, and flags concentration or seasonal risks that could affect future top‑line momentum.
Data provided by:
The Fly
The FlyNu Skin (NUS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$227.81M
Dividend Yield5.11%
Average Volume (3M)745.00K
Price to Earnings (P/E)―
Beta (1Y)1.24
Revenue Growth-15.44%
EPS Growth-319.79%
CountryUS
Employees2,800
SectorConsumer Defensive
Sector Strength42
IndustryHousehold & Personal Products
Share Statistics
EPS (TTM)-4.45
Shares Outstanding48,676,636
10 Day Avg. Volume574,295
30 Day Avg. Volume744,997
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)0.59
Price to Sales (P/S)0.32
P/FCF Ratio10.31
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1
Revenue Forecast (FY)$1.43B
Nu Skin Business Overview & Revenue Model
Company Description
Nu Skin Enterprises, Inc. (NUS) is a global enterprise dedicated to the creation and worldwide distribution of beauty and wellness solutions. The company's diverse product offerings encompass advanced skincare systems, such as the ageLOC Spa and a...
How the Company Makes Money
Nu Skin makes money primarily by selling its beauty and wellness products through a direct-selling (multi-level) distribution channel. The company generates revenue when products are purchased from Nu Skin by its independent salesforce (often refe...
Nu Skin Earnings Call Summary
Earnings Call Date:Aug 10, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 04, 2026
Earnings Call Sentiment Neutral
The call presented a mixed picture: strong product momentum and engagement around Prysm iO, improved core gross margin, cost reductions in G&A, and disciplined liquidity position are notable positives. However, sizable non-cash goodwill and deferred tax charges materially impacted reported earnings, adjusted operating margins declined, recruiting and leadership development remain weak, and the India launch was delayed. Near-term FX headwinds and modest operating cash flow further temper the outlook. On balance, the company shows encouraging strategic traction and product adoption but faces meaningful near-term financial and operational headwinds.Positive Updates
Quarterly Revenue
Q2 2026 revenue of $320.1 million (includes ~1% / $4M FX headwind). Full-year revenue guidance updated to $1.28–$1.35 billion (FY FX headwind ~1%).
Negative Updates
Significant Non-Cash Accounting Charges
Recorded a $78.9 million non-cash goodwill impairment related to the Rhyz manufacturing reporting unit and a $167.5 million non-cash valuation allowance on U.S. deferred tax assets, producing reported EPS of negative $5.14 for the quarter.
Read all updates
Q2-2026 Updates
Positive
Negative
Quarterly Revenue
Q2 2026 revenue of $320.1 million (includes ~1% / $4M FX headwind). Full-year revenue guidance updated to $1.28–$1.35 billion (FY FX headwind ~1%).
Read all positive updates
Company Guidance
Nu Skin updated Q3 revenue guidance to $310–$340 million (with an expected 2–3% foreign currency headwind) and Q3 EPS of $0.00–$0.09 reported (adjusted $0.10–$0.20), and revised full‑year revenue to $1.28–$1.35 billion (≈1% FX headwind) with reported FY EPS of −$4.90 to −$4.73 (adjusted $0.70–$0.90) and an adjusted effective tax rate of ~35%; management expects to place 50,000–60,000 Prysm iO devices by year‑end (vs. >39,000 placed to date, up ~30% QoQ, and 2.5 million scans, up ~25% QoQ). The company plans $5–$10 million of cash‑based organizational transition costs through year‑end excluded from adjusted results and also excluded the Q2 non‑cash charges (a $78.9M goodwill impairment and a $167.5M deferred tax valuation allowance) from adjusted guidance; for context Q2 revenue was $320.1M, gross margin 68.2% (core 77.7%), adjusted operating margin 6.1%, cash $189.6M, debt $213.7M and Q2 operating cash flow $10.6M.Nu Skin Financial Statement Overview
Summary
Income Statement
32
Negative
Balance Sheet
56
Neutral
Cash Flow
44
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.38B | 1.49B | 1.73B | 1.97B | 2.23B | 2.70B |
| Gross Profit | 951.49M | 1.03B | 1.18B | 1.36B | 1.59B | 2.02B |
| EBITDA | 39.32M | 262.41M | -78.83M | 202.98M | 174.97M | 368.48M |
| Net Income | -216.39M | 160.20M | -146.59M | 8.60M | 104.78M | 147.27M |
Balance Sheet | ||||||
| Total Assets | 1.12B | 1.41B | 1.47B | 1.81B | 1.82B | 1.91B |
| Cash, Cash Equivalents and Short-Term Investments | 189.64M | 239.84M | 197.99M | 267.82M | 278.51M | 354.81M |
| Total Debt | 263.74M | 364.25M | 478.23M | 607.33M | 520.52M | 503.79M |
| Total Liabilities | 578.79M | 600.07M | 817.46M | 984.50M | 923.67M | 993.71M |
| Stockholders Equity | 542.74M | 805.24M | 651.46M | 821.97M | 897.30M | 912.77M |
Cash Flow | ||||||
| Free Cash Flow | 10.78M | 46.01M | 70.16M | 60.15M | 49.01M | 72.97M |
| Operating Cash Flow | 50.81M | 80.29M | 111.74M | 118.64M | 108.06M | 141.58M |
| Investing Cash Flow | -39.60M | 170.66M | -37.96M | -134.50M | -67.08M | -88.73M |
| Financing Cash Flow | -79.16M | -202.40M | -133.18M | 10.73M | -99.50M | -104.70M |
Nu Skin Technical Analysis
Negative
5.08
Price Trends
5.15
Negative
5.96
Negative
7.68
Negative
Market Momentum
-0.13
Positive
36.07
Neutral
23.43
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NUS, the sentiment is Negative. The current price of 5.08 is below the 20-day moving average (MA) of 5.09, below the 50-day MA of 5.15, and below the 200-day MA of 7.68, indicating a bearish trend. The MACD of -0.13 indicates Positive momentum. The RSI at 36.07 is Neutral, neither overbought nor oversold. The STOCH value of 23.43 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NUS.
Nu Skin Risk Analysis
Nu Skin disclosed 12 risk factors in its most recent earnings report. Nu Skin reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Nu Skin Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | $5.53B | 93.96 | 5.18% | ― | 31.23% | -42.14% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
58 Neutral | $1.29B | -14.03 | -6.27% | 2.17% | -7.00% | -246.78% | |
56 Neutral | $2.35B | -4.32 | -15.12% | ― | -3.57% | -32.30% | |
53 Neutral | $30.51B | -125.35 | -6.29% | 1.74% | 0.71% | 71.47% | |
51 Neutral | $227.81M | -1.05 | -29.42% | 4.72% | -15.44% | -319.79% | |
47 Neutral | $78.08M | -2.66 | -47.84% | ― | -6.45% | -44.06% |
* Consumer Defensive Sector Average
NUS
Nu Skin
4.70
-6.74
-58.91%
EL
The Estée Lauder Companies
84.27
-1.05
-1.23%
COTY
Coty
2.74
-2.12
-43.62%
EPC
Edgewell Personal Care
28.45
5.75
25.36%
ELF
e.l.f. Beauty
92.51
-27.93
-23.19%
SKIN
Beauty Health
0.60
-1.52
-71.70%
Nu Skin Corporate Events
Business Operations and StrategyShareholder Meetings
Nu Skin Shareholders Approve Expanded Long-Term Incentive Plan
Positive
May 29, 2026
At its May 28, 2026 annual meeting, Nu Skin Enterprises’ stockholders approved an amended and restated 2024 Omnibus Incentive Plan that increases the share reserve by 2,850,000 shares and extends the plan’s term to May 28, 2036, enhanc...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.